KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Alnylam Pharmaceuticals (ALNY) Long-Term Debt Issuances (2021 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Long-Term Debt Issuances for 3 consecutive years, with -$680000.0 as the latest value for Q4 2025.

  • For Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to -$680000.0; the TTM value through Dec 2025 reached -$1.5 million, down 100.14%, while the annual FY2025 figure was $645.7 million, N/A changed from the prior year.
  • Long-Term Debt Issuances hit -$680000.0 in Q4 2025 for Alnylam Pharmaceuticals, up from -$777000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $1.0 billion in Q3 2022 and bottomed at -$250.0 million in Q3 2021.
  • Average Long-Term Debt Issuances over 3 years is $191.4 million, with a median of -$728500.0 recorded in 2022.
  • On a YoY basis, Long-Term Debt Issuances climbed as much as 506.76% in 2022 and fell as far as 506.76% in 2022.
  • Alnylam Pharmaceuticals' Long-Term Debt Issuances stood at -$250.0 million in 2021, then skyrocketed by 99.69% to -$777000.0 in 2022, then increased by 12.48% to -$680000.0 in 2025.
  • According to Business Quant data, Long-Term Debt Issuances over the past three periods came in at -$680000.0, -$777000.0, and $1.0 billion for Q4 2025, Q4 2022, and Q3 2022 respectively.